Neuro-rheumatology is a fast-growing field. Better testing and imaging have increased recognition of once-infrequent diagnoses, such as neuro-sarcoidosis and amyloid beta-related angiitis. Concurrently, the rapid expansion of immunotherapy options to treat cancer and their untoward neurological side effects have increased the frequency of referrals to both neurologists and rheumatologists. Identifying and treating neurologic manifestations of…
Search results for: diabetes
Point-of-Care Uric Acid Testing
In June 2022, I listened to several presentations on gout at EULAR’s European Congress of Rheumatology. Most began with data confirming a sad truth that we, as rheumatology providers, are all aware of: too many patients are taking subtherapeutic doses of urate-lowering therapy (ULT).1,2 Recommendations from the American College of Physicians in 2017 advocated for…
A World of Difference: Updates from the Global Rheumatology Summit
The second annual Global Rheumatology Summit focused on climate change, conflict and migration, as well as other global issues in rheumatology.
Zoledronic Acid vs. Oral Bisphosphonates: Osteoporosis Treatments & the Risk of Developing Osteonecrosis of the Jaw
A study from Amigues et al. found that bisphosphonate-associated osteonecrosis of the jaw is rare in patients with osteoporosis and may occur more often in patients treated with injectable zoledronic acid than in those treated with the oral bisphosphonates.
Rheumatology Medications with Limited Safety Data: How Do We Use Them in Pregnant Patients?
How does a rheumatologist treat a pregnant woman when many medications are not approved for pregnancy or safety data are limited?
To Treat or Not to Treat? The Great Debate on Treatment of Subclinical Rheumatoid Arthritis
PHILADELPHIA—One of the great advancements in the field of rheumatology in recent years has been the increased understanding of various stages of disease in rheumatoid arthritis (RA), including what is termed subclinical rheumatoid arthritis. However, questions remain regarding whether to treat patients with subclinical disease and whether treatment of these patients has implications in preventing…
COVID-19: Strategies to Protect Adult & Pediatric Patients
An ACR Convergence 2022 session provided practical updates on ways to best protect pediatric & adult patients with rheumatic disease from COVID-19.
Evolution of Medicare’s Merit-Based Incentive Payment System: MIPS Value Pathways
In November, the CMS finalized 12 MIPS Value Pathways (MVP) in the Quality Payment Program, including a rheumatology MVP. In 2023, clinicians can opt to report via traditional MIPS, the rheumatology MVP or both.
Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022
PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…
Rheumatologist Organizes Medical Mission to Ukraine
Early in 2022, a few months into the invasion of Ukraine by Russian troops, Paula Rackoff, MD, a rheumatologist and clinical associate professor at NYU Grossman School of Medicine, New York, felt an urgency to head to the region to assist the many refugees fleeing for the border with Poland. Dr. Rackoff canceled a planned…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 52
- Next Page »